GlaxoSmithKline PLC Price Rallies On Dividend Lift

GlaxoSmithKline (LON: GSK) reveals sales up 1% and earnings up 4%.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The shares of GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) soared 45p to 1,600p during afternoon trading after the pharmaceutical giant today announced its full-year results.  

The FTSE 100 member, which supplies 900 million vaccine doses to 170 countries and employs nearly 100,000 people, reported a 1% rise in turnover to £26.4bn.

Glaxo also boasted core earnings per share stepping-up 4% to 112.2p, which the group said was “in line with financial guidance”.  

The statement also highlighted operating profits flat at £8bn.

The company claimed “strong” cash generation, with full-year net cash flow up 5% to £7.3bn. The dividend was lifted 5% to 78p per share.

Sir Andrew Witty, Glaxo’s chief executive, said:

“GSK’s performance in 2013 represented further strong delivery for the Group.  We met our guidance with core EPS growth of 4% and sales growth of 1% (+3% ex-divestments) and returned £5.2 billion to shareholders via further growth in the dividend and our continuing share buy-back programme.” 

“We also delivered the most productive period of R&D output in the Company’s history and led the sector for new medicine approvals.”

Sir Andrew added that GlaxoSmithKline’s financial success provided the firm with the flexibility to “fund organic investment and restructuring programmes as well as our ongoing commitment to a growing dividend.

Of course, whether today’s full-year results as well as the wider prospects for the healthcare sector both combine to make GlaxoSmithKline a ‘buy’ right now is something only you can decide.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Douglas does not own any share mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »